Manhattan Research Report Provides a Framework for Pharma to Navigate the Physician Social Media Landscape

Manhattan ResearchPharmaceutical and healthcare market research company Manhattan Research releases a new report providing in-depth data and analysis to help healthcare marketers, agencies, and publishers assess the physician social media landscape. The report found that the majority of U.S. physicians are using professional user-generated content in some form, primarily on blogs, open message boards, and other online media. In contrast, less than 20 percent of U.S. physicians have visited closed professional online communities despite high interest in these types of forums, representing a challenge for marketers seeking to leverage social media as an engagement tool. "Physician Social Media: Benchmarking Adoption and Assessing Strategic Opportunities" provides a framework for pharma companies to approach physician social media, discusses why traction of professional communities remains low, and explores challenges and opportunities for harnessing physician use of social media content.

"Framing the social media landscape is a critical first step in understanding the growing audience of physicians interacting with one another online," said James Avallone, Senior Digital Healthcare Analyst at Manhattan Research. "Since physicians' primary consumption of professional social media is happening outside the walls of existing closed physician-only communities, marketers need to evaluate other engagement opportunities, such as distributed content or niche communities."

"Physician Social Media: Benchmarking Adoption and Assessing Strategic Opportunities" draws from Manhattan Research's Taking the PulseĀ® v10.0 study conducted in Q1 2010 via online and offline survey methodology among 2,033 U.S. practicing physicians.

For more information about the report and its table of contents, please visit http://www.manhattanresearch.com/physician-social-media

About Manhattan Research Reports
Manhattan Research offers in-depth reports on important trends in physician and consumer use of digital media and technology for health. The report series draws from interviews conducted with nearly 20,000 physicians and consumers about their behaviors, attitudes, and future interests as it relates to their use of the Internet and other technologies for health and treatment decisions. Each PDF report includes a written analysis, supporting graphs and data, and strategic takeaways. For more information, please visit http://www.manhattanresearch.com/reports.

About Manhattan Research
Manhattan Research, a Decision Resources, Inc. company, is a leading market research and advisory services firm for global pharmaceutical and healthcare companies. For more information, visit http://www.manhattanresearch.com.

About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at http://www.decisionresourcesinc.com.

Most Popular Now

BioMotiv and Bristol-Myers Squibb announce the lau…

BioMotiv, a mission-driven drug development accelerator associated with The Harrington Project for discovery and development, that advances breakthrough discoveries from ...

CEPI and GSK announce collaboration to strengthen …

CEPI, the Coalition for Epidemic Preparedness Innovations, and GSK announced a new collaboration aimed at helping the global effort to develop a vaccine for the 2019-nCoV...

Sandoz completes acquisition of Aspen's Japanese o…

Sandoz today announced that it has successfully completed the acquisition of the Japanese business of Aspen Global Incorporated (AGI), a wholly owned subsidiary of Aspen ...

Sanofi brain-penetrant BTK inhibitor meets primary…

The Sanofi Phase 2b study evaluating its investigational BTK (Bruton's tyrosine kinase) inhibitor (SAR442168), an oral, brain-penetrant, selective small molecule, achieve...

Roche reports very strong results in 2019

In 2019, Group sales rose 9% to CHF 61.5 billion and core EPS grew 13%, ahead of sales. The core operating profit increased 11%, reflecting the strong underlying business...

Sanofi completes acquisition of Synthorx, Inc.

Sanofi announced the successful completion of its acquisition of Synthorx, Inc. ("Synthorx") for $68 per share in cash. "The acquisition of Synthorx perfectly aligns w...

Merck donates one billionth praziquantel tablet

Merck, a leading science and technology company, today announced that it has already donated 1 billion tablets of praziquantel, the standard medication for the treatment ...

WHO, China leaders discuss next steps in battle ag…

The Director-General of the World Health Organization (WHO), Dr Tedros Adhanom Ghebreyesus, met President Xi Jinping of the People's Republic of China in Beijing. They sh...

Bayer and Nuvisan create new research unit in Berl…

Bayer AG today announced that it entered into a definitive agreement to transfer a large part of its Berlin-based small molecule research unit to Nuvisan, an internationa...

FDA approves first drug for treatment of peanut al…

Today the U.S. Food and Drug Administration approved Palforzia [Peanut (Arachis hypogaea) Allergen Powder-dnfp] to mitigate allergic reactions, including anaphylaxis, tha...

Can bilingualism protect the brain even with early…

A study by York University psychology researchers provides new evidence that bilingualism can delay symptoms of dementia. Alzheimer's disease is the most common form of d...

Poliovirus therapy shows potential as cancer vacci…

A modified form of poliovirus, pioneered at Duke Cancer Institute as a therapy for glioblastoma brain tumors, appears in laboratory studies to also have applicability for...